AI assistant
Sending…
Vanda Pharmaceuticals Inc. — Director's Dealing 2022
Aug 29, 2022
33390_dirs_2022-08-29_80703325-8c7c-45a3-a92e-33ed8d656b1b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2022-08-26
Reporting Person: Birznieks Gunther (SVP, Business Development)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-26 | Common Stock | M | 1250 | $3.12 | Acquired | 190057 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-08-26 | Employee Stock Option (Right to Buy) | $3.12 | M | 1250 | Disposed | 2022-12-06 | Common Stock (1250) | Direct |
Footnotes
F1: The option vested in 48 equal monthly installments beginning on December 7, 2012.
More from Vanda Pharmaceuticals Inc.
Regulatory Filings
2026
Jun 5
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 5
Interim / Quarterly Report
2026
May 7
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Board/Management Information
2026
Apr 22
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Feb 24
Regulatory Filings
2026
Feb 23
Director's Dealing
2026
Feb 19